Teva Pharmaceutical Industries Limited (TEVA)
Automate Your Wheel Strategy on TEVA
With Tiblio's Option Bot, you can configure your own wheel strategy including TEVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TEVA
- Rev/Share 14.626
- Book/Share 16.3426
- PB 3.836
- Debt/Equity 2.3536
- CurrentRatio 1.1083
- ROIC 0.0474
- MktCap 27833073741.0
- FreeCF/Share 0.5039
- PFCF 48.1541
- PE 39.0818
- Debt/Assets 0.4284
- DivYield 0
- ROE 0.1107
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TEVA | Goldman | -- | Buy | -- | $24 | June 6, 2025 |
| Initiation | TEVA | Truist | -- | Buy | -- | $25 | May 28, 2025 |
| Upgrade | TEVA | JP Morgan | Neutral | Overweight | -- | $23 | May 12, 2025 |
News
Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceutical Industries Limited ( TEVA ) UBS Global Healthcare Conference 2025 November 10, 2025 8:45 AM EST Company Participants Richard Francis - President, CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.
Read More
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Brainsway Ltd.
Read More
TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.
Read More
Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working
Published: November 05, 2025 by: CNBC Television
Sentiment: Positive
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's driving growth, and much more.
Read More
Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 Earnings
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Teva Pharmaceuticals stock surges 12% as branded drug sales outperform
Published: November 05, 2025 by: Invezz
Sentiment: Positive
Teva Pharmaceutical Industries Ltd. stock rose 12% after the company reported stronger-than-expected third-quarter results, buoyed by robust growth in its branded drug portfolio.
Read More
Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Blood pressure medicine recalled over high levels of cancer-causing chemical
Published: October 30, 2025 by: New York Post
Sentiment: Negative
More than half a million bottles of Prazosin Hydrochloride have been recalled over high levels of a chemical compound that could cause cancer, the FDA said.
Read More
Teva Vs. Viatris: Who Will Dominate In President Trump's America?
Published: October 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceuticals and Viatris occupy leading positions in the generic drugs market, valued at more than $613 billion in 2030. Each of them has advantages and "dark spots" in their portfolios of FDA-approved drugs and product candidates relative to the rival. By reading this article, you will learn which stock, Viatris or Teva, is more attractive in the long term.
Read More
Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.
Read More
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
Published: October 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY® (risperidone) as a once-monthly extended-release injectable suspension as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder (BD-I) in adults. The approval is based on existing clinical data for UZEDY, coupled with Model-Informed Drug Development (MIDD) methodologies that leverage previous findings on the safety and efficacy of …
Read More
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Positive
Wall Street is slowly beginning to understand that Teva Pharmaceutical Industries Limited is rapidly transforming from a generic medication supplier into one of the key players in the CNS treatment market. So, global sales of Austedo, widely used among neurologists for the treatment of tardive dyskinesia, reached $498 million in Q2 2025, an increase of 21.2% quarter-on-quarter. On September 20, Teva announced additional clinical data showing that taking Austedo XR led to significant improvements in social and emotional well-being.
Read More
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.
Read More
Teva Pharmaceutical Industries Limited - Special Call
Published: September 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceutical Industries Limited - Special Call Company Participants Christopher Stevo - Senior Vice President of Investor Relations & Competitive Intelligence Eric Hughes - Executive VP of Global R&D and Chief Medical Officer Christine Fox - Executive VP of U.S. Commercial Business Conference Call Participants Christoph Correll, MD David Amsellem - Piper Sandler & Co., Research Division Jason Gerberry - BofA Securities, Research Division Leszek Sulewski - Truist Securities, Inc., Research Division Michael DiFiore Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Presentation Operator Welcome to the Olanzapine LAI TEV-'749 Phase III SOLARIS Data Presentation Conference Call. My name …
Read More
Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
Published: September 17, 2025 by: Business Wire
Sentiment: Neutral
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California Teva will host a conference call for analysts and investors on Monday, September 22, 2025, at 11:00 am ET to discuss these data To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Even.
Read More
Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Richard Francis - President, CEO & Director Conference Call Participants Thibault Boutherin - Morgan Stanley, Research Division Presentation Thibault Boutherin Equity Analyst Okay. So I think we'll start.
Read More
TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?
Published: September 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Teva expects 2025 generics growth to be flat to low single digit, with U.S. trends and the Japan divestment influencing results.
Read More
US FDA approves Teva Pharmaceuticals' generic obesity drug
Published: August 28, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' cheaper generic version of Novo Nordisk's older weight-loss drug, Saxenda, the Israel-based company said on Thursday.
Read More
Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”
Published: August 19, 2025 by: Business Wire
Sentiment: Neutral
GOLETA, Calif.--(BUSINESS WIRE)--Teva unveils AW25 footwear collection.
Read More
Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Positive
Teva is transforming, with management delivering on profit growth, specialty drug expansion, and improving its balance sheet—yet the stock remains undervalued. Specialty products like AUSTEDO and UZEDY are driving margin improvement, while partnerships and cost-cutting support a credible turnaround. Despite lingering legal and debt risks, Teva's low valuation offers a favorable risk/reward for patient investors willing to look past old headlines.
Read More
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
Read More
Teva CEO: Our supply chain puts us in a strong position
Published: July 30, 2025 by: CNBC Television
Sentiment: Positive
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.
Read More
Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript
Published: July 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Christopher J. Stevo - Senior Vice President of Investor Relations & Competitive Intelligence Eliyahu Sharon Kalif - Executive VP & CFO Eric A.
Read More
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Teva Pharm Q2 profit beats estimates as branded drugs gain
Published: July 30, 2025 by: Reuters
Sentiment: Positive
Teva Pharmaceutical Industries reported a higher than expected rise in second-quarter profit, helped by strong sales gains of its branded drugs to treat migraines, Huntington's disease and schizophrenia.
Read More
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.
Read More
Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevention study showed that AJOVY (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in reducing frequency, duration and severity of migraine attacks in patients with chronic and episodic migraine.1
Read More
About Teva Pharmaceutical Industries Limited (TEVA)
- IPO Date 1982-02-16
- Website https://www.tevapharm.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Richard D. Francis
- Employees 37000